Nephria Bio

Executive Summary

Nephria Bio is a pre-clinical medical device company developing Project Nephron, a wearable artificial kidney system designed to transform dialysis for end-stage renal disease (ESRD) patients. Current dialysis restricts patients to clinic-based treatments, severely impacting mobility and quality of life. Nephria's device aims to enable continuous, ambulatory therapy with personalized treatment, potentially reducing hospital visits and improving outcomes. The company is based in Cambridge, Massachusetts, and was founded in 2020. As a pre-clinical entity, Nephria Bio faces significant technical and regulatory hurdles, including miniaturization, biocompatibility, and safety validation. The wearable artificial kidney market is nascent but holds substantial promise, with several competitors pursuing similar goals. Nephria's success hinges on demonstrating reliable device performance in pre-clinical models and securing partnerships or funding to advance toward first-in-human studies. The company's platform could address a large unmet need in nephrology, but early-stage risks remain high.

Upcoming Catalysts (preview)

• Q3 2026Preclinical prototype validation data60% success
• Q4 2026Strategic partnership or licensing deal40% success
• Q1 2027Regulatory submission for first-in-human trial (e.g., IDE)30% success